Abstract
Disease-specific therapy is available for only a handful of neuromuscular disorders, including Pompe disease—a debilitating metabolic myopathy caused by a deficiency of the lysosomal glycogen-catabolising enzyme, acid α-glucosidase (GAA). Enzyme replacement therapy (ERT) with recombinant human GAA, alglucosidase alfa, was approved (by the US Food and Drug Administration and the European Medicines Agency) for Pompe disease more than a decade ago. Since this approval, clinical trials and multiple investigator-led long-term studies have shown that most patients with late-onset Pompe disease experience a steady decline in multiple outcome measures (particularly those assessing respiratory function) after initial improvements over the first few years with ERT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.